Aldn-084 Jun 2026

| Study | Species | Dose (mg kg⁻¹) | Duration | NOAEL | Findings | |-------|---------|----------------|----------|-------|----------| | | Mouse | 200 (PO) | Single | 150 | No mortality; mild GI irritation at 200 mg | | 14‑day repeat dose | Rat | 0, 10, 30, 100 | PO QD | 30 | No clinical signs; slight elevation of ALT at 100 mg (reversible) | | 28‑day GLP | Dog | 0, 5, 15, 45 | PO QD | 15 | No ocular, cardiac, or CNS adverse effects; slight decrease in lymphocyte count at 45 mg (within physiological range) | | Genotoxicity | In vitro Ames, mouse micronucleus | — | — | Negative | No mutagenic or clastogenic activity | | Safety pharmacology | Telemetry‑monitored rats | 30 (IV) | Single | 30 | No QTc prolongation; HR & BP stable | | Reproductive toxicity | Rat (segment‑specific) | 15 (PO) | Gestation days 6‑20 | 15 | No embryofetal malformations; slight reduction in fetal weight (≤ 5 %) |

: If you're tasked with creating a text without existing information, consider what "ALDN-084" could represent. For example, is it a code for a chemical compound, a product name, or perhaps an identifier for a piece of artwork or media? ALDN-084

Developed using advanced protein engineering, ALDN-084 aims to restore the body’s ability to break down toxic substrates, preventing the progressive organ damage that characterizes many rare genetic conditions. The Mechanism of Action | Study | Species | Dose (mg kg⁻¹)

It would most likely be investigated first in adults with major depressive disorder, especially those with inadequate response to existing therapies. The Mechanism of Action It would most likely